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Heparanase (HPSE) is the dominant mammalian endoglycosidase and important tumorigenic, angiogenic, and pro-
metastatic molecule. Highest levels of HPSE activity have been consistently detected in cells possessing highest
propensities to colonize the brain, emphasizing the therapeutic potential for targeting HPSE in brain metastatic
breast cancer (BMBC). Lapatinib (Tykerb) is a small-molecule and dual inhibitor of human epidermal growth factor
receptor1 and 2 (EGFR and HER2, respectively) which are both high-risk predictors of BMBC. It was approved by
the US Food and Drug Administration for treatment of patients with advanced or metastatic breast cancer.
However, its role is limited in BMBC whose response rates to lapatinib are significantly lower than those for
extracranial metastasis. Because HPSE can affect EGFR phosphorylation, we examined Roneparstat, a non-
anticoagulant heparin with potent anti-HPSE activity, to inhibit EGFR signaling pathways and BMBC onset using
lapatinib-resistant clones generated from HER2-transfected, EGFR-expressing MDA-MB-231BR cells. Cell growth,
EGFR pathways, and HPSE targets were assessed among selected clones in the absence or presence of
Roneparstat and/or lapatinib. Roneparstat overcame lapatinib resistance by inhibiting pathways associated with
EGFR tyrosine residues that are not targeted by lapatinib. Roneparstat inhibited the growth and BMBC abilities of
lapatinib-resistant clones. A molecular mechanism was identified by which HPSE mediates an alternative survival
pathway in lapatinib-resistant clones and is modulated by Roneparstat. These results demonstrate that the
inhibition of HPSE-mediated signaling plays important roles in lapatinib resistance, and provide mechanistic
insights to validate the use of Roneparstat for novel BMBC therapeutic strategies.
Neoplasia (2015) 17, 101–113Introduction
The family of epidermal growth factor receptors (HER/ErbB) plays
pivotal roles in the regulation of breast cancer progression and
metastasis [1]. One of the four HER family members, epidermalgrowth factor receptor1 (EGFR, HER1, or ErbB1) is overexpressed in
25% to 80% of breast cancers [2], while another, epidermal growth
factor receptor2 (HER2, neu, or ErbB2), is amplified and/or
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dual inhibitor of EGFR and HER2. Its use was approved by the US
Federal and Drug Administration for therapeutic combinations with
capecitabine for the treatment of patients overexpressing HER2 that
have received prior therapy, including anthracycline and the
humanized HER2 antibody trastuzumab (Herceptin) [4]. Brain
metastatic breast cancer (BMBC) is frequently detected in patients
overexpressing HER2 and EGFR [5]. However, either systemic or
recent targeted therapies using lapatinib are only minimally effective
with BMBC response rates far lower (approximately 5%) than those
with extracranial metastases [6–8].
Molecular mechanisms countering lapatinib resistance are not fully
understood and subject of intense investigation because of their
therapeutic implications. Roles of lapatinib in cell survival and
proliferation are dependent and selective upon EGFR and HER2
phosphorylation and tyrosine kinase catalytic activity [4,6–8]. For
example, EGFR and HER2 signal through the phosphoinositide 3-
kinase (PI3K) pathway and lapatinib was shown to block downstream
signaling via PI-3K/Akt and mitogen-activated protein kinase
(MAPK) pathways in breast cancer cells by interrupting baseline
and ligand-stimulated activity [6,7,9]. However, not all EGFR/
HER2-expressing breast cancer cells respond to lapatinib, particularly
if cells overexpress EGFR such as the brain-seeking MDA-MB-
231BR variant [5,7].
Heparanase (HPSE) is the dominant mammalian endoglycosidase
(endo-β-D-glucuronidase), cleaving heparan sulfate (HS) to frag-
ments which retain biological activity. By this action, HPSE releases
important HS/heparin-binding angiogenic and growth factors,
affecting their levels and biological potency [10–12]. HPSE functions
are not limited to HS cleavage or the release of HS-sequestered
growth factors but also affect clustering, shedding, and mitogenic
activity of HS proteoglycans, e.g., cell surface syndecans, which are
the main HPSE targets [10–13]. Heparanase activity correlates with
the metastatic potential of cancer cells, a notion that is well-supported
experimentally and clinically [10–19]. Of relevance, highest HPSE
levels have been consistently detected in tumor cells selected to
possess highest propensities to colonize the brain [14–16] with the
recent evidence for its expression in patient-isolated breast cancer
circulating tumor cells competent to generate brain metastasis in
xenografts [20]. Apart from its well-characterized enzymatic activity,
heparanase was also shown to exert enzymatic-independent functions,
e.g., acting as a signal transducer and regulator of cell adhesion [21]
and cytoskeletal dynamics [22]. A recent report also showed that
HPSE augmented EGFR phosphorylation that correlated with head
and neck tumor progression [18]. Heparanase can thus initiate
broad effects that dramatically alter the microenvironment and
stimulate tumor cell growth and metastasis. Altogether, these notions
raised the following questions – Is HPSE implicated in lapatinib
resistance of breast cancer cells expressing EGFR and HER2? If so, by
which mechanism(s)?
We hypothesized that HPSE is implicated in mechanisms of lapatinib
resistance of breast cancer cells expressing EGFR/HER2, and promotes
alternative signaling pathways which are not inhibited by lapatinib, with
HPSE inhibition suppressing tumor growth and BMBC. To examine
this, we used Roneparstat, a chemically modified heparin lacking anti-
coagulant activity and a potent inhibitor of heparanase activity [19,23].
We selected and used lapatinib-resistant clones generated from the
human brain-colonizing MDA-MB-231BR breast cancer cell line [24],
then studied Roneparstat-mediated actions related to the lapatinibresistance in these clones. We show that the inhibition of HPSE
activity by Roneparstat overcomes lapatinib resistance and suppresses cell
growth in vitro and BMBC onset in vivo. These findings provide the
molecular basis to potentially employ Roneparstat in therapeutic
approaches of lapatinib-resistant breast cancers, particularly breast cancer
brain metastasis.Materials and Methods
Tissue Culture, Establishment of Lapatinib-Resistant Clones,
and Clones Characterization
The human brain metastatic MDA-MB-231BR cell line was obtained
from Dr. Toshiyuki Yoneda (The University of Texas Health Science
Center-San Antonio, TX). It was derived from MDA-MB-231 parental
cells by six sequential cycles of selection followed by cell injection into the
internal carotid artery of nude mice, and resulting in augmented abilities
to generate brain metastasis over the parental counterpart [24]. The
MDA-MB-231BR clone transfected with HER2 (named BR for brevity;
original cells possess low HER2 levels) (Figure S3) [5] was provided by
Dr. Patricia Steeg (National Cancer Institute, Bethesda, MD). MDA-
MB-231 parental, MDA-MB-231BR, and BR variant cell lines were
authenticated by short tandem repeat (STR)DNA fingerprinting analyses
for 16 loci, and data compared to the database of the Characterized Cell
Line Core at MD Anderson Cancer Center (Houston, TX). Lapatinib-
resistant cell lines were obtained from surviving BR cells exposed to
increasing lapatinib concentrations (0.1, 0.5, 1, 5, and 10 μmol/L) in
DMEM/F12 culture medium for 4 to 5 weeks. Resistance at each dose
was assessed by comparing the growth of each resistance derivative to
parental BR cells. Next, surviving cells were treated chronically in vitro
with lapatinib (1 μmol/L) [25]. Medium supplemented with this
lapatinib concentration was changed every 2 to 3 days with cells being
continuously exposed to lapatinib for a three-months period, and
resulting in the generation of BR lapatinib-resistant (BR-Lr) clones.
Lapatinib-sensitive (BR-Ls) clones were also obtained from BR cells using
the limiting dilution method (single-cell colonies) in 96-well plates [25].
BR-Lr and BR-Ls clones were cultured in Dulbecco’s Modified Eagle
Medium plus F12 (DMEM/F12) (Invitrogen, Carlsbad, CA) supple-
mented with 10% fetal bovine serum (FBS) (Invitrogen), and 1%
penicillin and streptomycin (Life Technologies). All BR-Lr clones were
cultured in a humidified, 5% CO2 incubator at 37°C, passaged twice
weekly along the same schedule, and used only at low passage and if
Mycoplasma negative. Experimental metastasis assays were periodically
performed to test cell in vivo tumorigenic abilities. These studies were
accomplished per protocol approved by the Institutional AnimalCare and
UseCommittee (IACUC) of BaylorCollege ofMedicine, and involved all
steps of animals sacrifice and amelioration of suffering. Cell cycle analyses
based upon fluorescence activated cell sorting (FACS) were carried
out using the FACSCalibur instrument at the flow cytometry core facility
of Baylor College of Medicine, and analyzed using a CellQuest software
(BD Bioscience).
Antibodies, Reagents, and Inhibitors
Primary antibodies includemouse anti-human heparanasemonoclonal
antibody which was obtained from Cedarlane Laboratories (Burlington,
NC). Rabbit anti-human heparanase was kindly provided by Dr. Israel
Vlodavsky (The Rappaport Institute-Technion, Haifa, Israel). The other
primary antibodies were purchased from Cell Signaling (Danvers, MA).
Secondary antibodies included: goat anti-rabbit IgG [H+L]-HRP and
goat anti-mouse IgG [H+L]-HRP that were purchased from Santa Cruz
Neoplasia Vol. 17, No. 1, 2015 Heparanase Mechanisms in Lapatinib-resistant Breast Cancer Brain Metastasis Zhang et al. 103Biotechnology (Santa Cruz, CA), while biotinylated universal anti-rabbit/
mouse IgG [H+L] was obtained from Vector Laboratories (Burlingame,
CA). Lapatinib (Tykerb) was purchased from Sellek, Inc. (Abilene, TX),
and Roneparstat (SST0001 or 100NA, RO-H) was provided by Sigma-
tau Research S.A. (Mendrisio, Switzerland) under a material transfer
agreement. Roneparstat’s chemical structure and functionalities as potent
HPSE inhibitor have been described elsewhere [19,23]. Based upon its
coefficient in lipid phase and the number of hydrogen bonds on theFigure 1. Selection and growth of lapatinib-resistant BR clones. A.
surviving HER2-transfected, EGFR expressing MDA-MB-231BR (name
exposing BR cells to increasing lapatinib concentrations (0.1, 0.5, 1
selection lasted for 4–5 weeks. Medium supplemented with lapatini
were treated chronically in vitro with this lapatinib concentration for 3
selected for amplification and characterization. B. Representative ce
activated cell sorting (FACS) and their quantitation. Bars represent th
considered statistically significant. C. Colony formation (soft-agar ass
(1 μM). Colonies of N50 μm in diameter size were counted and colony
Values are expressed as mean ± SD of triplicate samples. P b .01 was
for experimental details.steroid, it is predicted that Roneparstat is able to penetrate the blood-
brain barrier or the blood-tumor barrier. Roneparstat was prepared as
a stock solution following the manufacturer’s instructions, and
diluted in culture medium directly before its use. The focal adhesion
kinase (FAK) inhibitor PF 573,228 was purchased from Sigma-
Aldrich (St. Louis, MO) and used treating cultured cells at
concentrations (30 to 100 nM) reported to significantly decrease
FAK phosphorylation without toxicity [26].Graph displaying the generation of lapatinib-resistant clones from
d BR for brevity) cells [7]. Resistant clones were developed by first
, 5 and 10 μmol/L in DMEM/F12 culture medium). This period of
b (1 μmol/L) [25] was changed every 2–3 days, and surviving cells
months. Afterwards, clones developing resistance to lapatinib were
ll cycle analyses of BR, BR-Ls and BR-Lr clones by fluorescence-
e mean ± SD of three independent determinations. *P b .01 was
ays) by BR and selected BR-Lr clones in the presence of lapatinib
number statistically quantified. All data were analyzed by ANOVA.
considered statistically significant. Refer toMaterials and Methods
Figure 1. (Continued.)
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Cells were serum-starved for 24 hours, then indicated proteins were
examined for expression levels by Western blotting, as previously
described [14,27]. Heparanase activity in cells and mouse serum was
examined using the heparan sulfate degrading enzyme assay kit
(TakaRa Mirus.Bio, Madison, WI) following the manufacturer’s
instructions, as previously reported [13,14,27].
Colony Forming Assays
Assays were performed as previously described [25,28]. Briefly, 1.5 ml
of DMEM containing 10% FBS and 0.5% low-melting agarose were
poured into 60-mm Petri dishes, in triplicate. The layer was covered with
HER2-transfected BR or BR-Lr clones in 1.5 ml of 0.35% low-melting
agarose containing DMEM/F12 supplemented with 10% FBS.Medium
was changed every 3 days and dishes were incubated for additional 2
weeks, then stained with crystal violet. Colonies of N50 μm in size
(diameter) were counted under a phase-contrast microscope and colony
numbers plotted. At least three independent experiments were performed
and data validated for statistical significance.
ELISA Assays
BR and selected lapatinib-resistant and sensitive BR clones (BR-Lr and
BR-Ls, respectively) were examined for levels of secreted HPSE using the
human heparanase ELISA kit (EIAab Science Ltd., Haifa, Israel),
following the manufacturer’s protocol. The kit provides a quantitative
HPSE determination in cell-conditionedmedia and lysates using a biotin-
conjugated polyclonal antibody specific for heparanase. HPSE concen-
tration was assessed by color changes induced by the biotin-conjugatedantibody and enzyme-conjugated avidin, and by comparing the O.D. of
samples to the standards supplied by the kit (for details refer to www.
eiaab.com). Syndecan-1 levels were examined in cell conditioned media
collected from BR-Lr, BR-Ls or HER2-transfected BR cells with or
without drugs treatment, using the human syndecan ELISA kit (Abcam,
Inc., Cambridge, MA), per protocol provided by the manufacturer
(Figures S1 and S2).
Immunohistochemistry
Proteins of interest were examined using formalin-fixed, paraffin-
embedded specimens of primary and BMBC tissues obtained from
models of experimental metastasis (xenografts). Sections were fixed with
4% formaldehyde in PBS, permeabilized with 0.1% Triton X-100, and
blocked with 10% normal goat serum followed by incubation with
indicated primary antibody (1:50 to 1:100 dilution) for 18 hours at 4°C,
then by the secondary antibody (1:400 dilution) incubation for 1 hr at
room temperature (25°C). Staining was performed using a Vectastain
ABC kit (Vector Laboratories, Burlingame, CA). Results were examined
by pathologists blinded to study groups. Positivity of staining was
distributed throughout a 0 to 3+ intensity scale: 0 corresponded to
background staining; 1+, weak staining; 2+, moderate staining; 3+,
strongest staining, pathologically assessed.
Experimental BMBC Mouse Model
Athymic nude mice (nu/nu, 5–6 weeks old) were purchased from
Harlan Sprague Dawley, Inc. (Indianapolis, IN), and maintained at
the accredited animal facility of Baylor College of Medicine (BCM).
All studies were conducted according to NIH animal use guidelines
C)
0
2
4
H
PS
E 
ac
tiv
ity
 (u
nit
/m
l) 
**
**
β-actin42 -
HPSE
65 -
kDa
50 -
A)
0
4
8
12
H
PS
E 
(p
g/m
l x
 10
3 ) **
B)
**
Conditioned medium
Lysate
Conditioned medium
Lysate
Figure 2. Heparanase (HPSE) expression and activity in HER2-transfected BR, lapatinib-sensitive and lapatinib-resistant selected clones
(BR-Ls and BR-Lr, respectively). A. Western blotting analyses showing expression of HPSE in its latent (65 KDa) and active (50 kDa) forms
[11,27]. They were performed as previously described [14,27]. B. Heparanase expression in cell lysates and conditioned medium of BR/
BR-Ls/BR-Lr cells by ELISA. C. Heparanase activity in cell lysates and conditioned medium of BR/BR-Ls/BR-Lr cells. HPSE activity was
assesses as previously described [13,14]. All data were analyzed for statistical significance. Values are expressed as mean ± SD of three
independent determinations. **P b .001, ANOVA. Refer to Materials and Methods for experimental details.
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Parental BR and BR-Lr cells were injected into the third mammary fat
pad (0.5 × 106 cells/cell line/mouse; n = 5 mice/treatment group) and
drug treatment began seven days following cell injection. Mice were
randomly divided into four treatment groups: 1) phosphate-buffered
saline (PBS, control); 2) lapatinib (30 mg/kg/day); 3) Roneparstat (30
mg/kg/day); 4) lapatinib plus Roneparstat (30 mg/kg/day each).
These reagents were delivered via Alzet osmotic pumps (DURECT
Corporation, Cupertino, CA). To examine additive roles of
Roneparstat and lapatinib inhibiting tumor growth, primary tumors
were monitored weekly, and tumor weight was calculated by the
following formula: tumor weight (mg) = d2 ×D/2, where d andD are the
shortest and the longest diameter, respectively. After 28 days of drug
treatment, primary tumors were excised and wet weights recorded. To
assess whether the combination of Roneparstat and lapatinib could
significantly inhibit BMBC after primary tumors were removed under
sterile surgical conditions, mice continued to receive drug treatment for
additional twoweeks by injecting drugs at same doses. Next, whole brains
were excised from the animals and fixed in Bouin’s solution. Serial
sections were analyzed by hematoxylin and eosin (H&E) staining to assess
presence of brain metastatic lesions. BMBC was analyzed by the Cri
Vectra Intelligent system (Cambridge Research & Instrumentation, Inc.,
Boston,MA) that is capable of visualizing and quantifying tumor cells at a
single-cell level (green color) [20].Statistical Analyses
At least three independent experiments were performed and all
results were validated by analysis of variance (ANOVA) performed on
the data with experiment specified as the random effect. Values are
expressed as mean ± SD of at least triplicate samples. P b .01 was
considered statistically significant.Results
Generation of Lapatinib-Resistant Clones fromHER2-Transfected
MDA-MB-231BR Cells
HER2-transfected MDA-MB-231BR (named BR for brevity) cells
were exposed to increasing concentrations of lapatinib (0.1–10 μmol/L
in DMEM/F12 containing 10% FBS medium) for 4–5 weeks.
Lapatinib-resistant BR clones (BR-Lr) were selected from surviving
cells exposed to highest concentration of lapatinib (10 μmol/L).
Clones were then selected following a chronic exposure to lapatinib
(1 μmol/L) for three months and subsequently characterized. This
lapatinib concentration was found to be sufficient to maintain
resistance to the drug and did not alter HER2 expression in these cells
(Figure S3) [25]. Five lapatinib-resistant single clones were obtained,
amplified by long-term culturing, and named BR-Lr1, BR-Lr2, etc
(Figure 1A). Lapatinib-resistant (BR-Lr) clones were also obtained
from original MDA-MB-231BR cells using the limiting dilution
106 Heparanase Mechanisms in Lapatinib-resistant Breast Cancer Brain Metastasis Zhang et al. Neoplasia Vol. 17, No. 1, 2015method in 96-well plates (Figure S3) [25]. Single clones were selected
in the absence of lapatinib, and the sensitivity of these clones to
lapatinib was tested by survival assays (Figure 1A) [25,28]. We used
BR-Lr1 and BR-Lr2 as lapatinib-resistant clones in all subsequent
experiments. Further, because BR-Ls cell growth characteristics wereFigure 3. Roneparstat and lapatinib inhibit EGFR and FAK-associated
BR-Lr2, respectively). A. Western blotting analysis of BR, BR-Lr1 and B
for 24 hours. Cells were then treated as indicated [PBS (control), Rone
at same dose (30 mg/kg/day)]. Following 24 hours incubation at 37°
analyses. Representative results are shown. β-actin indicates equal
formation of BR-Lr clones. Bars represent the mean ± SD of three in
significant. C. Western blotting analyses showing the inhibition of fo
BR-Lr clones. The FAK inhibitor PF 573,228 (Sigma-Aldrich, St. Louis, M
avoid off-targets effects [26]. Representative results are shownwith B
(control). D. FAK inhibition by PF 573,228 decreases colony-forming ab
independent determinations. **P b 0.001, ANOVA. E. Roneparstat
addition of recombinant human HPSE (rHPSE). Western blotting analy
BR/BR-Lr1/BR-Lr2 following treatment with Roneparstat (30 mg/kg/d
indicates equal loading (control). All data were analyzed for statis
independent determinations. **P b 0.001, ANOVA. Refer to Materialhighly similar to parental BR cells, we used the latter as experimental
control in all experiments.
To define the nature of growth inhibition of BR parental and
selected BR-Lr/BR-Ls clones, considering that cancer cell prolifera-
tion is largely driven by cell cycle alterations, we examined the cellsignaling in HER2-transfected BR and BR-Lr clones (BR, BR-Lr1 and
R-Lr2 cells. Cells were seeded in six-well plates and serum-starved
parstat (30 mg/kg/day), lapatinib (1 μM) without or with Roneparstat
C, cells were collected and cell lysates prepared for Western blot
loading (control). B. Roneparstat and lapatinib inhibited the colony
dependent determinations. *P b 0.01 was considered statistically
cal adhesion kinase (FAK) to modulate EGFR/FAK/ERK signaling in
O) was used in all experiments at concentrations (30-100 nM) that
R cells analyzed in parallel as control. β-actin indicates equal loading
ilities of BR-Lr clones. Values are expressed as mean ± SD of three
-mediated reduction of HPSE downstream effects is rescued by
ses expression of HPSE-mediated targets MMP-9 and COX-2 [14] in
ay) in the absence or presence of rHPSE (500 ng/ml) [12]. β-actin
tical significance. Values are expressed as mean ± SD of three
s and Methods for experimental details.
Figure 3. (Continued.)
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grew at higher rates and had a lower percentage (15–20%) cells in G1
while higher one (20–25%) in S phase compared to BR or BR-Ls
clones (Figure 1B) [28]. Next, we examined BR-Lr growth abilities
employing colony formation assays. Lapatinib-resistant cells exhibited a
significantly higher colony formation (52% and 56% for BR-Lr1 and
BR-Lr2, respectively) compared to BR cells, suggesting that lapatinib-
resistant clones possess stronger proliferative capabilities (Figure 1C).
Heparanase Expression, Activity, and Secretion in BR/BR-Ls/
BR-Lr Cells
To test the hypothesis that heparanase plays an important role in
mechanisms of lapatinib resistance, BR/BR-Ls/BR-Lr cells wereexamined for HPSE expression (Western blotting/ELISA assays),
HPSE secretion (ELISA), and activity (HS-degrading enzyme assays).
Higher HPSE expression was detected in BR-Lr1/2 clones, notably
the 50 kDa active HPSE subunit (Figure 2A) [11]. Similarly, HPSE
was approximately 1.2 to 1.5 fold higher in BR-Lr than BR or BR-Ls
cell lysates, however increased (1.5-fold) heparanase activity was
observed in the cell conditioned medium of all lapatinib-resistant BR
clones compared to BR counterparts (Figure 2, B and C, respectively).
Third, to determine whether elevated HPSE activity enhances
shedding of target HS proteoglycans, e.g., cell surface syndecan-1
[13,29] in lapatinib-resistant BR cells, syndecan-1 levels were
analyzed in the cell conditioned medium by ELISA. Higher
(~50%) syndecan-1 expression was detected in BR-Lr clones
108 Heparanase Mechanisms in Lapatinib-resistant Breast Cancer Brain Metastasis Zhang et al. Neoplasia Vol. 17, No. 1, 2015compared to parental BR cells (Figure S1), providing further
indication that HPSE activity may be relevant in lapatinib resistance
mechanisms driving an aggressive tumor phenotype [30].
Inhibition of HPSE-Mediated Signaling by Roneparstat in
BR-Lr Cells
To evaluate roles of heparanase conferring lapatinib resistance, we
blocked heparanase using Roneparstat, then investigated the extent of
HPSE-mediated signaling inhibition in BR-Lr clones. Abilities of HPSE
to affect ERK/FAK and EGFR-associated signaling have been previously
reported [12,18]. Phosphorylated FAK (pFAK) levels were greatly
decreased in BR-Lr clones, treated either with Roneparstat or Roneparstat
additive to lapatinib, and compatible with decreased EGFR (Y845) and
ERK phosphorylation (Figure 3A). Importantly, while Roneparstat
affected the phosphorylation of EGFR at tyrosine position 1173
(pEGFR, Y1173), it also reduced the phosphorylation of pEGFR at
992 position (Y992) which is not a target of lapatinib (Figure 3A) [7].
Second, we examined effects of Roneparstat treatment on the growth of
BR-Lr cells. Cell growth was profoundly inhibited by Roneparstat, either
alone or in the presence of lapatinib (Figure 3B). This suggests that
Roneparstat can inhibit the phosphorylation of HPSE downstream
signaling, specifically pEGFR (Y845), pFAK and pMAPK, thus
decreasing BR-Lr cell growth abilities [26]. Third, to determine whetherB) HPSE knockdown inhibits colony
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SMARTpool siRNA (siHPSE 10 nM, 30 nM) or non-target control (siCt
Next, cell lysates were prepared and HPSE protein levels were determ
examined by colony formation assays (B). Representative results ar
analyzed for statistical significance. Values are expressed as mean ±
Materials and Methods for experimental details.the inhibition of phosphorylated FAK (pFAK) modulates cell growth,
we treated cells with the FAK inhibitor PF 573,228. The phosphory-
lation of EGFR (Y845), Src, and ERK1/2 expression was reduced by PF
573,228 treatment (Figure 3C). Of note, BR-Lr clones were
significantly more sensitive to PF 573,228, exhibiting a strong
reduction (70% to 75%) in colony formation (Figure 3D). Fourth,
we examined the expression ofMMP-9 and COX2which are known to
be regulated by HPSE [27]. The expression of MMP-9 and Cox-2 was
affected by Roneparstat with reduced MMP-9 and COX-2 protein
levels following Roneparstat treatment. This reduction was rescued by
the addition of recombinant humanHPSE (rHPSE) (Figure 3E; see also
Figure S2). Lastly, we validated the effect of HPSE inhibition on
lapatinib resistance employing siRNA approaches. HPSE-specific
siRNA (SMART pool siRNA) [14] inhibited HPSE expression in
both BR and BR-Lr clones (Figure 4A). Cell colony formation abilities
also depended upon siRNA inhibition and correlated with HPSE
siRNA concentration-dependent effects (Figure 4B).
Roneparstat Sensitizes Lapatinib-Mediated Inhibition of Cell
Growth and BMBC Onset
Heparanase roles in tumor invasion and metastasis are long-known
[10,11] with a recent report implicating Roneparstat to alter tumor
growth by heparanase activity inhibition [23]. Because of the presence of-forming abilities of BR-Lr clones
BR-Lr2
NT
siCTRL 50nM
siHPSE 10nM
siHPSE 50nM
* 
** 
HPSE
β-actin
BR-Lr2
A concentration-dependent
-Lr clones. Cells (BR, BR-Lr1, BR-Lr2) were transfected with HPSE
rl) for 48 hours [14], then treated with lapatinib (1 μM) for 24 hours.
ined by Western blot analyses (A) while cell growth abilities were
e shown. β-actin was used for equal loading (control). Data were
SD of triplicate samples. *P b 0.01; **P b 0.001, ANOVA. Refer to
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Roneparstat could overcome lapatinib resistance by inhibiting HPSE
actions in these cells. Accordingly, we examined effects of Roneparstat on
primary tumor growth andmetastasis by injecting BR-Lr clones into nude
mice followed by various drug treatments [PBS control, lapatinib (1 μM)
without or with Roneparstat (30 mg/kg per day), and Roneparstat alone
(30 mg/kg per day)]. These reagents were administered to animals by
Alzet osmotic pumps after 7 days of tumor cell injection into mammary
fat pads. They were delivered for 28 days with weekly monitoring for
tumor development. Once observed, tumors were removed and their
extent, number, size, and wet-weight were assessed among treatment
modalities. Tumor size was approximately 40% smaller in Roneparstat/
lapatinib-treated animals than lapatinib alone with the tumor weight alsoFigure 5. Roneparstat and lapatinib inhibit breast tumor growth and
(BR) and selected BR-Lr clones (BR-Lr1, BR-Lr2) were injected into the
treatment group). Tumor growth was monitored weekly by measuring
harvested and photographed. Representative images are shown (top
groups (bottom). Values are expressed as mean ± SD of triplicate sam
from animals with BMBC following BR-Lr cell injection. Sections wer
(Cambridge Research & Instrumentation, Inc.) which highlights and en
[20]. Representative images of BR-Lr-induced BMBC are shown for
represented by the number of single tumor cells detected and ana
different treatment groups were removed when they reached the sam
Vectra-inForm. Data were analyzed for statistical significance. Values
.001, ANOVA. Refer to Materials and Methods for experimental detareduced (62% reduction; P b .001) in Roneparstat/lapatinib-treated
group compared to lapatinib only-treated animals (Figure 5A).
To analyzewhether combinatorial Roneparstat and lapatinib treatment
inhibited BR-Lr cell-induced BMBC, delivery of drugs continued for
additional two weeks within animal sub-groups. Mice were then
sacrificed, brains surgically removed, and examined for BMBC presence.
A distinct reduction (N60%; P b .001; primary tumors within treatment
groups were removed when reaching the same size) of the number of
BMBC cells in Roneparstat-treated mice was observed compared to
lapatinib alone or control groups (Figure 5, B and C). These results
suggest that Roneparstat is able to significantly inhibit BR-Lr cell-
mediated tumor growth and brainmetastasis. Second, to evaluatewhether
the inhibition effect on tumor growth andmetastasis resulted fromHPSEBMBC onset in xenografts. A. HER2-transfected parental BR cells
third mammary fat pad (0.5 × 106 cells/cell line/mouse; n = 5mice/
length and width with a digital caliper. Tumors were subsequently
). Tumor weight was calculated and compared among treatment
ples. **P b .001, ANOVA. B. Hematoxylin and eosin (H&E) sections
e randomly selected and analyzed by the Cri-Vectra-inForm system
umerates single tumor cells (in green) but not adjacent stromal cells
the various treatments. C. Quantification of BMBC tumor burden
lyzed by the Cri-Vectra-inForm system [20]. Primary tumors from
e size, then the extent of BMBC tumor burden wasmeasured by Cri-
are expressed as mean ± SD of triplicate samples. *P b .01; **P b
ils.
Figure 5. (Continued.)
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according to drug treatment. We detected HPSE activity to be
significantly lower (60% to 75% reduction; P b .001) in Roneparstat
and Roneparstat/lapatinib-treated animal groups compared to lapatinib
alone (Figure S4). Third, to translate signaling results (Figure 3) to in vivo
settings, we investigated phosphorylation levels of EGFR (Y845), FAK
and ERK1/2 in BR-Lr-induced BMBC tumors.We observed levels to be
reduced following Roneparstat and Roneparstat/lapatinib treatments of
experimental enimals (Figure 6, A–C). Altogether, findings indicate that
Roneparstat sensitizes lapatinib inhibition of tumor growth in BR-Lr
clones by a regulation of heparanase activity and heparanase downstream
signaling and targets.
Discussion
The molecular mechanisms of resistance to lapatinib in breast cancer
remain poorly understood, particularly in brain metastatic breast
cancer (BMBC). The present study was designed to identify
mechanisms by which cells expressing EGFR/HER2, both high-risk
predictors for BMBC onset, develop resistance to lapatinib. We
hypothesized that compensatory signaling originating independently
of the EGFR/HER2 pathways may exist and be responsible to impart
added resistance to the drug. We demonstrated the relevance ofHPSE in lapatinib resistance with Roneparstat inhibitor regulating
downstream pathways that lapatinib fails to inhibit, and reducing
breast tumor growth and brain metastasis.
Several breast cancer model cell systems have known capabilities of
generating BMBC (e.g., MDA-MB-231P/BR, MDA-MB-435,
MDA-MB-361 and MDA-MB-468) [5,7,31]. However, reasons by
which these cells acquire resistance to lapatinib treatment are still
unclear and understudied. Among these model cell systems, MDA-
MB-231BR is most studied because of its high propensities to
generate BMBC in experimental metastasis assays. Further, a report
showed that lapatinib inhibited the phosphorylation of HER2/EGFR
downstream signaling proteins modulating cell proliferation/migra-
tion abilities and BMBC propensities of MDA-MB-231BR cells,
either with or without HER2 presence [7].
Heparanase is well-known to be a potent tumorigenic, angiogenic
and pro-metastatic molecule with highest activity levels found in cells
selected to possess highest propensities to colonize the brain
[14,16,27]. For example, we have previously demonstrated that
HPSE translocation to nucleolus enhances MDA-MB-231BR cell
proliferation through the activation of Topoisomerase I [14] and that
HPSE inhibition by siRNA or microRNA can inhibit breast cancer
cell growth, invasion and brain metastasis [27]. Our laboratory has
A) Roneparstat and lapatinib inhibit EGFR phosphorylation in BMBC
Control                              Lapatinib Roneparstat Lapatinib + Roneparstat
BR
BR-Lr1
pEGFR
(Y845)
200 µm1  
100 µm
B) Roneparstat and lapatinib inhibit FAK phosphorylation in BMBC
Control                                  Lapatinib Roneparstat Lapatinib + Roneparstat
BR
pFAK
BR-Lr1
100 µm
100 µm
C) Roneparstat and lapatinib inhibit ERK phosphorylation in BMBC
BR-Lr1
BR
pERK1/2
Control                                 Lapatinib Roneparstat Lapatinib + Roneparstat
100 µm
100 µm
Figure 6. Roneparstat and lapatinib inhibit EGFR/FAK/ERK phosphorylation of BR-Lr cell-induced BMBC. A–C. Immunohistochemical BMBC
analyses of treated HER2-transfected BR and BR-Lr clones displaying reduced EGFR (Y845) (A), FAK (B), and ERK1/2 (C) phosphorylation in
response to Roneparstat and lapatinib treatment. Data obtained using the BR-Lr1 clone are shown and representative of all BR-Lr clones
investigated. Immunohistochemistry was performed as described inMaterials and Methods (refer also to reference [7]).
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and in the cross-talk between tumor cells and vascular brain
endothelium within the initial steps leading to BMBC onset [22].
Here, we examined roles of heparanase in newly-developed lapatinib
resistant clones derived from HER2-transfected, EGFR-expressing
MDA-MB-231BR cells (named BR for brevity) following their
exposure to increasing and sequential lapatinib doses. The rationale
was to extend the previous investigations using the MDA-MB-231BRmodel [7] with the knowledge that HPSE can augment EGFR
phosphorylation reported in other cancer settings [18]. Our findings
indicate that HPSE activity is involved in mechanisms of lapatinib
resistance in the BR model system: the potent HPSE inhibitor
Roneparstat can significantly sensitize lapatinib inhibition to decrease
breast cancer cell growth (colony-forming abilities in soft-agar assays)
and brain metastasis in xenografts. We provide evidence that HPSE
activity is elevated in lapatinib-resistant BR clones, and that the
112 Heparanase Mechanisms in Lapatinib-resistant Breast Cancer Brain Metastasis Zhang et al. Neoplasia Vol. 17, No. 1, 2015activity in these clones promoted an enhanced phosphorylation of
EGFR (Y845), FAK, ERK1/2, and increased cell growth (Figure 3).
Results also indicate that Roneparstat is a potent HPSE inhibitor that
can effectively block these signaling pathways to diminish the
formation of BMBC in an experimental animal model (Figure 5).
A potential pathway by which HPSEmodulate lapatinib resistance is
the heparanase/syndecan-1 axis. A recent publication has reported that
this axis can be blocked in myeloma cells by Roneparstat [23]. Further,
syndecan-1 is increased in several breast cancer types, including HER2
overexpressors [32]. Our data show that levels of shed syndecan-1 was
significantly increased in BR-Lr clones compared to parental BR cells
(Figure S1). Roneparstat significantly decreased shed syndecan-1 levels
in a concentration-dependent manner. Of note, Roneparstat-mediated
reduction of shed syndecan-1 was rescued by recombinant human
heparanase (rHPSE) in these cells (Figure S2). This can partially explain
Roneparstat effectiveness in mechanisms of lapatinib resistance. A
possible role of syndecan-1 is to act as a molecular “bridge” and link to
FAK/Src signaling since FAK/Src can bind to the cytoplasmic domain
of syndecan-1 [29]. Heparanase can enhance syndecan-1 shedding
resulting in the activation of FAK/Src signaling and downstream effects
at specific EGFR phosphorylation sites, e.g., Y845 (Figures 3, A and
C). Other studies have also demonstrated that the activation of ERK
requires HPSE activity [30] and that exogeneous HPSE up-regulated
FAK/ERK phosphorylation through enhanced fibroblast growth factor
receptor binding and signaling [12]. Our findings are consistent with
these reports.
Our study has limitations as we did not examine whether the
selected BR-Lr clones are also resistant to other HER inhibitors such
as trastuzumab targeting HER2 [28] or whether our findings also
apply to estrogen receptor-positive human breast cancer cells that
develop resistance to lapatinib [25]. Further, lapatinib may be mostly
ineffective in BMBC because it has a mediocre brain permeability and
may fail to penetrate the brain at sufficient and consistent doses, at
least for reliable ones having anti-tumor (cytotoxic) effects. Tumor
cells isolated from brain of mice treated with lapatinib can retain
lapatinib sensitivity in in vitro conditions [8]. Similarly, the increase
of HPSE expression and activity in BR-Lr clones correlated with
lapatinib resistance but did not confer resistance to the drug; and how
HPSE regulates and/or works in conjunction with other growth/
regulatory factors to promote BMBC will have to be elucidated.
Lastly, the combinatorial lapatinib-Roneparstat treatment can directly
occur at the primary tumor affecting its growth, and that the extent of
BMBC (metastasis) be a secondary effect influenced by the primary
tumor burden. Although the extent of BMBC regulation following
treatment was determined after removing primary tumors with the
same size, this remains a possibility to be investigated in future studies
(see also Ref. [33]). Regardless, our data put forward the notion that
Roneparstat, a small-molecule non-anticoagulant heparin and potent
HPSE inhibitor, is effective against BMBC modalities without any
evident toxicities or side effects either in cell cultures or animals.
Roneparstat inhibition of HPSE and EGFR signaling demonstrate its
dramatic effects altering the BMBC microenvironment and the cross-
talk between neoplastic and normal brain cells to diminish brain
metastasis [15].
In conclusion, we have identified a molecular mechanism of
lapatinib resistance in brain metastatic breast cancer, and demon-
strated that Roneparstat can overcome lapatinib resistance and inhibit
tumor growth and metastasis. Specifically, the combination of
Roneparstat and lapatinib inhibited tumor cell growth in vitro andbrain metastasis in vivo, presumably through dual targeting of HPSE-
mediated pathways within cells of the BMBC microenvironment.
Roneparstat outcomes in ongoing clinical trials (Phase I in multiple
myeloma) will provide useful information for its potential as a novel
therapeutic agent for treatment of BMBC.
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